NVNO Insider Trading

Insider Ownership Percentage: 16.30%
Insider Buying (Last 12 Months): $60,941.14
Insider Selling (Last 12 Months): $0.00

enVVeno Medical Insider Trading History Chart

This chart shows the insider buying and selling history at enVVeno Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

enVVeno Medical Share Price & Price History

Current Price: $6.29
Price Change: Price Increase of +0.06 (0.96%)
As of 02/6/2023 06:07 PM ET

This chart shows the closing price history over time for NVNO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]

enVVeno Medical Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Francis DuhayDirectorBuy7,751$6.14$47,591.1420,911View SEC Filing Icon  
6/30/2022Sanjay ShrivastavaDirectorBuy1,000$3.85$3,850.003,888View SEC Filing Icon  
6/27/2022Robert Andrew BermanCEOBuy2,500$3.80$9,500.00210,236View SEC Filing Icon  
11/19/2021Robert Andrew BermanCEOBuy2,000$7.43$14,860.00View SEC Filing Icon  
11/16/2021Robert Andrew BermanCEOBuy2,000$7.87$15,740.00View SEC Filing Icon  
8/25/2021Matthew JenusaitisDirectorBuy1,300$7.70$10,010.004,842View SEC Filing Icon  
6/16/2021Robert GrayDirectorBuy2,000$6.25$12,500.005,572View SEC Filing Icon  
5/21/2021Marc H. GlickmanSVPBuy1,600$5.90$9,440.001,600View SEC Filing Icon  
5/18/2021Robert Andrew BermanCEOBuy3,000$5.47$16,410.003,736View SEC Filing Icon  
5/17/2021Francis DuhayDirectorBuy9,492$5.33$50,592.3613,160View SEC Filing Icon  
8/20/2020Holding S.A. BiodyneMajor ShareholderSell75,000$0.27$20,250.003,255,433View SEC Filing Icon  
8/18/2020Holding S.A. BiodyneMajor ShareholderSell50,000$0.34$17,000.003,255,433View SEC Filing Icon  
8/14/2020Holding S.A. BiodyneMajor ShareholderSell50,000$0.31$15,500.003,255,433View SEC Filing Icon  
8/3/2020Holding S.A. BiodyneMajor ShareholderSell70,000$0.32$22,400.003,255,433View SEC Filing Icon  
7/30/2020Holding S.A. BiodyneMajor ShareholderSell25,000$0.32$8,000.003,255,433View SEC Filing Icon  
7/20/2020Holding S.A. BiodyneMajor ShareholderSell150,000$0.43$64,500.003,255,433View SEC Filing Icon  
7/16/2020Holding S.A. BiodyneMajor ShareholderSell50,000$0.38$19,000.003,255,433View SEC Filing Icon  
7/6/2020Holding S.A. BiodyneMajor ShareholderSell6,450$0.39$2,515.503,255,433View SEC Filing Icon  
7/1/2020Holding S.A. BiodyneMajor ShareholderSell45,000$0.38$17,100.003,255,433View SEC Filing Icon  
6/29/2020Holding S.A. BiodyneMajor ShareholderSell68,094$0.39$26,556.663,255,433View SEC Filing Icon  
6/26/2020Holding S.A. BiodyneMajor ShareholderSell80,000$0.38$30,400.003,255,433View SEC Filing Icon  
6/24/2020Holding S.A. BiodyneMajor ShareholderSell55,530$0.42$23,322.603,255,433View SEC Filing Icon  
6/22/2020Holding S.A. BiodyneMajor ShareholderSell63,186$0.46$29,065.563,255,433View SEC Filing Icon  
6/19/2020Holding S.A. BiodyneMajor ShareholderSell80,000$0.46$36,800.003,255,433View SEC Filing Icon  
6/17/2020Holding S.A. BiodyneMajor ShareholderSell203,100$0.48$97,488.003,255,433View SEC Filing Icon  
6/15/2020Holding S.A. BiodyneMajor ShareholderSell100,000$0.42$42,000.003,255,433View SEC Filing Icon  
6/11/2020Holding S.A. BiodyneMajor ShareholderSell100,000$0.39$39,000.003,255,433View SEC Filing Icon  
6/2/2020Holding S.A. BiodyneMajor ShareholderSell220,000$0.33$72,600.003,361,016View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for enVVeno Medical (NASDAQ:NVNO)

23.05% of enVVeno Medical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NVNO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

enVVeno Medical Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2022Two Sigma Advisers LP17,500$0.11M0.0%-52.7%0.185%Search for SEC Filing on Google Icon
11/14/2022UBS Oconnor LLC149,720$0.94M0.0%+26.8%1.581%Search for SEC Filing on Google Icon
11/10/2022Dimensional Fund Advisors LP21,489$0.14M0.0%N/A0.227%Search for SEC Filing on Google Icon
7/26/2022Sepio Capital LP10,800$41K0.0%N/A0.114%Search for SEC Filing on Google Icon
7/18/2022Arthur M. Cohen & Associates LLC24,000$91K0.0%+60.0%0.253%Search for SEC Filing on Google Icon
5/11/2022ACT Capital Management LLC401,200$2.56M2.7%+52.8%4.237%Search for SEC Filing on Google Icon
2/15/2022Kingdon Capital Management L.L.C.219,180$1.44M0.2%N/A2.315%Search for SEC Filing on Google Icon
2/14/2022Perceptive Advisors LLC781,615$5.15M0.1%N/A8.255%Search for SEC Filing on Google Icon
2/3/2022ACT Capital Management LLC262,500$1.73M1.3%N/A2.772%Search for SEC Filing on Google Icon
1/24/2022Arthur M. Cohen & Associates LLC14,000$92K0.0%N/A0.148%Search for SEC Filing on Google Icon
8/17/2021Worth Venture Partners LLC82,886$0.57M0.2%-17.7%0.974%Search for SEC Filing on Google Icon
8/16/2021State Street Corp20,200$0.14M0.0%N/A0.237%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC63,753$0.44M0.0%+75.8%0.749%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.258,680$1.78M0.0%+483.6%3.038%Search for SEC Filing on Google Icon
8/12/2021AIGH Capital Management LLC346,885$2.38M0.4%-19.1%4.074%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC11,512$77K0.0%N/A0.135%Search for SEC Filing on Google Icon
5/19/2021Worth Venture Partners LLC100,714$0.67M0.3%N/A1.183%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC23,567$0.16M0.0%N/A0.277%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC11,512$77K0.0%N/A0.135%Search for SEC Filing on Google Icon
5/18/2021Jane Street Group LLC21,745$0.15M0.0%N/A0.255%Search for SEC Filing on Google Icon
5/14/2021Dimensional Fund Advisors LP10,821$72K0.0%N/A0.127%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp15,360$0.10M0.0%N/A0.181%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC36,268$0.24M0.0%N/A0.426%Search for SEC Filing on Google Icon
5/12/2021UBS Group AG17,061$0.11M0.0%+1,326.5%0.201%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC26,107$0.23M0.0%N/A1.008%Search for SEC Filing on Google Icon
2/14/2020Jane Street Group LLC112,263$62K0.0%-16.0%0.626%Search for SEC Filing on Google Icon
8/15/2019Jane Street Group LLC77,915$81K0.0%N/A0.435%Search for SEC Filing on Google Icon
2/15/2019Jane Street Group LLC31,692$47K0.0%N/A0.270%Search for SEC Filing on Google Icon
12/13/2018Vanguard Group Inc52,720$0.14M0.0%N/A0.450%Search for SEC Filing on Google Icon
11/23/2018Vanguard Group Inc.52,720$0.14M0.0%N/A0.450%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
enVVeno Medical logo
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
Read More on enVVeno Medical

Today's Range

Now: $6.29
Low: $6.20
High: $6.49

50 Day Range

MA: $5.26
Low: $4.54
High: $6.30

52 Week Range

Now: $6.29
Low: $3.35
High: $7.93


6,961 shs

Average Volume

17,648 shs

Market Capitalization

$59.57 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of enVVeno Medical?

enVVeno Medical's top insider investors include:
  1. Robert Andrew Berman (CEO)
  2. Francis Duhay (Director)
  3. Robert Gray (Director)
  4. Matthew Jenusaitis (Director)
  5. Sanjay Shrivastava (Director)
  6. Marc H Glickman (SVP)
  7. Gmt Capital Corp (Major Shareholder)
Learn More about top insider investors at enVVeno Medical.